Cargando…
Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to th...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Academy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743860/ https://www.ncbi.nlm.nih.gov/pubmed/29021510 http://dx.doi.org/10.2183/pjab.93.038 |
_version_ | 1783288640662667264 |
---|---|
author | TAKEUCHI, Tsutomu |
author_facet | TAKEUCHI, Tsutomu |
author_sort | TAKEUCHI, Tsutomu |
collection | PubMed |
description | Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to the patients and societies. Here, I will review recent progress of the biological treatment in the immune-inflammatory diseases by focusing on the rheumatoid arthritis, the disease characterized by persistent polyarthritis leading to joint destruction and disability with autoimmune features, as a role model. |
format | Online Article Text |
id | pubmed-5743860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japan Academy |
record_format | MEDLINE/PubMed |
spelling | pubmed-57438602018-01-04 Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease TAKEUCHI, Tsutomu Proc Jpn Acad Ser B Phys Biol Sci Review Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to the patients and societies. Here, I will review recent progress of the biological treatment in the immune-inflammatory diseases by focusing on the rheumatoid arthritis, the disease characterized by persistent polyarthritis leading to joint destruction and disability with autoimmune features, as a role model. The Japan Academy 2017-10-11 /pmc/articles/PMC5743860/ /pubmed/29021510 http://dx.doi.org/10.2183/pjab.93.038 Text en © 2017 The Japan Academy This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review TAKEUCHI, Tsutomu Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
title | Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
title_full | Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
title_fullStr | Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
title_full_unstemmed | Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
title_short | Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
title_sort | treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743860/ https://www.ncbi.nlm.nih.gov/pubmed/29021510 http://dx.doi.org/10.2183/pjab.93.038 |
work_keys_str_mv | AT takeuchitsutomu treatmentofrheumatoidarthritiswithbiologicalagentsasatypicalandcommonimmunemediatedinflammatorydisease |